Literature DB >> 16848314

[Inhibitory effect of iguratimod on TNFalpha production and NF-kappaB activity in LPS-stimulated rat alveolar macrophage cell line].

Ye Jiang1, Wei Lü, Shu-Qin Yu, Lin Yao, Guang-Lin Xu, Xi-Ran Zhang.   

Abstract

AIM: To investigate the effect of iguratimod (T-614), a non-steroidal anti-inflammatory drug, on TNFalpha mRNA expression and TNFalpha production, and on the activity of nuclear factor-kappaB (NF-kappaB) in the rat alveolar macrophage cell line (NR8383) activated by LPS.
METHODS: NR8383 cells were pretreated with T-614 (13.4, 26.7, 53.4 micromol x L(-1)), then were stimulated with LPS. The production of TNFalpha in the supernatant of NR8383 was assayed by enzyme-linked immunosorbent assay (ELISA). The TNFalpha mRNA level was determined by a semi-quantitative PCR assay. Assessment of the NF-kappaB DNA binding activity was performed by an ELISA kit.
RESULTS: T-614 inhibited LPS-stimulated mRNA expression and production of TNFalpha in a concentration-dependent manner, as well as the activity of NF-kappaB. The IC50 value of effect of T-614 on TNFalpha level was 26.2 micromol x L(-1).
CONCLUSION: The inhibitory effect of T-614 on the production of TNFalpha in LPS-stimulated NR8383 cells may be mediated by suppression of NF-kappaB activity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16848314

Source DB:  PubMed          Journal:  Yao Xue Xue Bao        ISSN: 0513-4870


  3 in total

Review 1.  Iguratimod: a valuable remedy from the Asia Pacific region for ameliorating autoimmune diseases and protecting bone physiology.

Authors:  Jie Li; Jun Bao; Jian Zeng; Aizhu Yan; Chunqiu Zhao; Qiang Shu
Journal:  Bone Res       Date:  2019-09-03       Impact factor: 13.567

Review 2.  Effectiveness of iguratimod as monotherapy or combined therapy in patients with rheumatoid arthritis: a systematic review and meta-analysis of RCTs.

Authors:  Chao-Jun Hu; Li Zhang; Shuang Zhou; Nan Jiang; Jiu-Liang Zhao; Qian Wang; Xin-Ping Tian; Xiao-Feng Zeng
Journal:  J Orthop Surg Res       Date:  2021-07-16       Impact factor: 2.359

Review 3.  Iguratimod as a New Drug for Rheumatoid Arthritis: Current Landscape.

Authors:  Sisi Xie; Shu Li; Jing Tian; Fen Li
Journal:  Front Pharmacol       Date:  2020-02-26       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.